Alerts will be sent to your verified email
Verify Email
ORTINGLOBE
|
Ortin Global
|
Venmax Drugs&Pharma
|
Parmax Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-57.26 % | -44.32 % | -1624.87 % |
|
5yr average Equity Multiplier
|
2.67 | -0.19 | 46.04 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 0.32 | 0.95 |
|
5yr Avg Net Profit Margin
|
-75.26 % | -30.94 % | -9.48 % |
|
Price to Book
|
6.58 | 2.96 | 0.0 |
|
P/E
|
0.0 | 0.0 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
597.13 Days | 0.0 | -161.05 Days |
|
Inventory Days
|
335.19 Days | 24.83 Days | 73.65 Days |
|
Days Receivable
|
448.05 Days | 0.0 | 40.27 Days |
|
Days Payable
|
649.97 Days | 189.56 Days | 328.05 Days |
|
5yr Average Interest Coverage Ratio
|
-2.05 | -318.36 | 1.16 |
|
5yr Avg ROCE
|
-24.19 % | -45.33 % | -9.94 % |
|
5yr Avg Operating Profit Margin
|
-55.65 % | -50.41 % | 3.93 % |
|
5 yr average Debt to Equity
|
0.64 | -0.64 | 17.42 |
|
5yr CAGR Net Profit
|
44.41 % | n/a | n/a |
|
5yr Average Return on Assets
|
-20.66 % | 187.49 % | -6.43 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
1.23 % | 23.13 % | 30.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-14.45 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Ortin Global
|
Venmax Drugs&Pharma
|
Parmax Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|